5 potential new drugs to watch for
Biogen Idec, Pfizer, Bristol-Myers and Celgene are among companies awaiting US approval of key treatments.
The Food and Drug Administration is set to announce its decision about several experimental medicines. The following are five potential treatments scheduled for approval during that period. All are key to the strategies of the companies that developed them.
The therapies are listed in chronological order, with the date representing the deadline for the FDA to make its ruling on each drug. Some of these dates can be delayed.
Rytary for Parkinson's disease is the lead drug candidate for the branded pharmaceutical division of Impax Laboratories (IPXL). Impax is a generic drug maker that's looking to boost revenue with branded products. In October, the company said it expected fourth-quarter revenue to decline by as much as 20% from third-quarter sales as Impax's generic business faces more competition. The company also is hoping to resolve manufacturing issues at a California plant after an FDA warning. Rytary looks approvable but may face some insurance coverage challenges early in its launch, according to an analysis by Leerink Swann. GlaxoSmithKline (GSK) has rights to sell the drug in most countries outside the U.S.
Celgene's (CELG) multiple myeloma drug pomalidomide slowed the progression of cancer and improved length of survival in patients, according to study results released in early December. The data seems to support approval by the FDA. Celgene seeks approval for pomalidomide as a treatment for patients who were previously treated with other drugs. William Blair analyst John Sonnier estimates there are about 100,000 relapsed multiple myeloma patients in the U.S. and Europe who have failed at least one prior therapy. Celgene CEO Robert Hugin previously called the drug a potential blockbuster.
ImmunoGen (IMGN) and Roche (RHHBY) are expected to win approval for the breast cancer treatment trastuzumab emtansine, or T-DM1. The drug combines ImmunoGen's chemotherapy with Roche's Herceptin to better target cancer. The companies are bullish on the potential success of T-DM1, and it looks like Roche negotiated a good deal for itself. In October, shares of ImmunoGen fell after the company disclosed royalty payments that Wall Street analysts and investors viewed as skimpy for the biotech company. ImmunoGen would get only 3% royalties on sales of the drug in the U.S. and abroad. The payments would only reach 5% if sales jump to more than $700 million in a single year.
Large pharmaceuticals Bristol-Myers Squibb (BMY) and Pfizer (PFE) know they have a potentially big-selling drug in the blood thinner Eliquis. The companies seek approval of the product for the prevention of stroke and a clotting blockage known as systemic embolism. The drug is considered more effective and much safer than the longtime standard of care, warfarin. Even though other new anti-clotting treatments made by Johnson & Johnson (JNJ), Bayer, and Boehringer Ingelheim are already approved, Eliquis is seen as a potential leader among the recent wave of improved therapies. In June, the FDA rejected the drug, saying that it wanted more proof of the medicine's effectiveness and safety. Both Pfizer and Bristol-Myers need new drugs as their former top-selling products lose sales to generic rivals. Eliquis is approved in Europe and Canada and it just won market clearance in Japan this week.
Biotech giant Biogen Idec (BIIB) was supposed to hear from the FDA about its experimental multiple sclerosis pill by late December. But the agency said it needed additional time to review the drug, known as BG-12. There are huge expectations on Wall Street and in the medical community for this drug, which would go head to head with Novartis' (NVS) Gilenya. The Novartis pill, approved in late 2010, was the first oral treatment approved for MS, a disabling disease that attacks the central nervous system. The disease, an important therapeutic area for Biogen, historically was treated with injected or infused drugs. BG-12 is considered a sure blockbuster for Biogen, which has seen its shares rise by more than a third in 2012.
More From Minyanville
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The solid report comes a month after the retailer closed all of its Canadian operations.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.